3118-68-1

Basic information

• Product Name: 3-Cyanobenzenesulfonamide
• Synonyms: Benzenesulfonamide, 3-cyano- (9CI);3-Cyanobenzenesulfonamide;3-Sulfamoylbenzonitrile;Benzenesulfonamide 3-cyano-;3-cyanobenzene-1-sulfonaMide
• CAS NO: 3118-68-1
• Molecular Formula: C₇H₆N₂O₂S
• Molecular Weight: 182.19974
• Product Categories: SULFONAMIDE
• Mol File: 3118-68-1.mol
• Article Data: 10

Chemical Properties

• Melting Point: 151-153°C
• Boiling Point: 392.5 °C at 760 mmHg
• Flash Point: 191.2 °C
• Appearance: UN3439
• Density: 1.47 g/cm³
• Vapor Pressure: 2.29E-06mmHg at 25°C
• Refractive Index: 1.626
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.56±0.60(Predicted)
• CAS DataBase Reference: 3-Cyanobenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Cyanobenzenesulfonamide(3118-68-1)
• EPA Substance Registry System: 3-Cyanobenzenesulfonamide(3118-68-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 7/9-22-24/25-26-36/37-38-51
• RIDADR: UN3439
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 3118-68-1(Hazardous Substances Data)

Usage

General Description

3-Cyanobenzenesulfonamide is a chemical compound with the molecular formula C7H6N2O2S. It is a sulfonamide derivative with a cyano group attached to the benzene ring. 3-Cyanobenzenesulfonamide is used in the synthesis of various pharmaceuticals, agrochemicals, and dyes. It also has potential applications in the field of medicinal chemistry, particularly in the development of new drugs for the treatment of various diseases. Additionally, 3-Cyanobenzenesulfonamide is considered to be a valuable intermediate in organic synthesis due to its versatile reactivity and potential for creating novel chemical structures. Overall, this compound has significant importance in both industrial and scientific applications.

InChI:InChI=1/C7H6N2O2S/c8-5-6-2-1-3-7(4-6)12(9,10)11/h1-4H,(H2,9,10,11)

Upstream product

• 4025-64-3 3-Carboxybenzenesulfonyl chloride 
• 636-76-0 3-sulfamoylbenzoic acid 
• 2237-30-1 m-cyanoaniline 
• 143-33-9 sodium cyanide 
• 56542-67-7 3-cyanobenzene sulfonyl chloride 

Downstream Products

• 628298-58-8 3-(aminomethyl)benzenesulfonamide 
• 857003-88-4 3,3'-azanediylbis(methylene)dibenzenesulfonamide 
• 670280-13-4 3-(aminomethyl)benzenesulfonamide hydrochloride 
• 1359027-37-4 N,N-bis[2-(dimethylamino)ethyl]-3-[5-(1-methyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl]benzenesulfonamide 
• 1359026-93-9 3-[5-(1-methyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl]benzenesulfonamide 
• 1359026-84-8 C₂₀H₁₇F₃N₆O₃S 
• 90000-88-7 N-hydroxy-3-sulfamoylbenzene carboximidamide 

Relevant articles and documents

EIF4E INHIBITORS AND USES THEREOF

The present invention provides compounds inhibiting elF4E activity and compositions and methods of using thereof.

Method for catalytic synthesis of N-benzyl benzene sulfonamide compounds by boric acid/oxalic acid catalytic system under microwave radiation

The invention discloses a method for catalytic synthesis of N-benzyl benzene sulfonamide compounds by a boric acid/oxalic acid catalytic system under microwave radiation. The method includes: adoptingbenzyl alcohol and derivatives thereof and benzene sulfonamide derivatives as raw materials, adopting the boric acid/oxalic acid system as a catalyst, and adopting fluorobenzene as a solvent; performing reaction in a microwave reactor under certain temperature and power conditions, performing vacuum concentration after reaction for a period of time, and subjecting a product to column chromatographic purification to realize efficient catalytic preparation of the N-benzyl benzene sulfonamide compounds. Compared with the prior art, the method has advantages of evidently higher reaction speed than that of conventional heating, mild reaction conditions, simplicity in operation, high yield, safety, low cost and environmental friendliness.

IMIDAZOPYRAZINE COMPOUNDS

Novel imidazopyrazine compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a viral infection, in particular a HCV, HRV, Sb and/or CVB in a patient in need thereof.